Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) Director Adeoye Y. Olukotun sold 11,350 shares of Arrowhead Pharmaceuticals stock in a transaction dated Friday, March 3rd. The shares were sold at an average price of $32.65, for a total value of $370,577.50. Following the completion of the transaction, the director now directly owns 7,867 shares of the company’s stock, valued at $256,857.55. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Arrowhead Pharmaceuticals Trading Down 4.8 %
Shares of ARWR stock opened at $30.79 on Tuesday. The company’s fifty day simple moving average is $34.64 and its 200-day simple moving average is $34.34. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $26.81 and a 52 week high of $51.11. The company has a market cap of $3.33 billion, a PE ratio of -20.95 and a beta of 1.05.
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) last released its quarterly earnings data on Monday, February 6th. The biotechnology company reported ($0.39) EPS for the quarter, missing the consensus estimate of $1.14 by ($1.53). Arrowhead Pharmaceuticals had a negative net margin of 54.31% and a negative return on equity of 34.73%. The company had revenue of $62.55 million during the quarter, compared to analysts’ expectations of $162.52 million. During the same period last year, the business earned ($0.60) earnings per share. The company’s revenue for the quarter was up 127.9% compared to the same quarter last year. Equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.4 EPS for the current fiscal year.
Analyst Ratings Changes
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the stock. Amalgamated Bank increased its position in shares of Arrowhead Pharmaceuticals by 2.4% during the third quarter. Amalgamated Bank now owns 73,081 shares of the biotechnology company’s stock worth $2,415,000 after acquiring an additional 1,724 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its position in shares of Arrowhead Pharmaceuticals by 2.7% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 19,382 shares of the biotechnology company’s stock worth $641,000 after acquiring an additional 506 shares during the last quarter. California Public Employees Retirement System increased its holdings in Arrowhead Pharmaceuticals by 14.4% in the third quarter. California Public Employees Retirement System now owns 234,142 shares of the biotechnology company’s stock valued at $7,738,000 after buying an additional 29,437 shares during the last quarter. Point72 Hong Kong Ltd increased its holdings in Arrowhead Pharmaceuticals by 3,242.0% in the third quarter. Point72 Hong Kong Ltd now owns 10,661 shares of the biotechnology company’s stock valued at $352,000 after buying an additional 10,342 shares during the last quarter. Finally, B. Riley Wealth Management Inc. bought a new stake in Arrowhead Pharmaceuticals in the second quarter valued at about $1,859,000. 65.46% of the stock is owned by hedge funds and other institutional investors.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC.
- Get a free copy of the StockNews.com research report on Arrowhead Pharmaceuticals (ARWR)
- Go Where the Money Is. Here’s 3 Top Bank Dividend Stocks to Buy
- Another Catalyst For Mullen Automotive Stock
- Solar Tech-Services; Nextracker Should Be On Your Radar
- Is American Lithium a Safe Bet as Demand for Lithium Soars
- Highwoods Properties, High-quality Real Estate for a Discount
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.